Accurate, balanced evidence-based information about medicines
Email this page
Print
Bookmark and share
Bigger
SmallerNPS RADAR May 2009 NPS RADAR May 2009
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain NPS RADAR>Brief Item>Health Professional Publication | Hydromorphone prolonged-release (Jurnista), a once-daily long-acting opioid, was listed on the Pharmaceutical Benefits Scheme on 1 May 2009. It is available as a restricted benefit for chronic severe disabling cancer or non-cancer pain not responding to non-opioid analgesics. |
| Lanthanum (Fosrenol) tablets for adults with chronic kidney disease who are on dialysis NPS RADAR>Brief Item>Health Professional Publication | Lanthanum (Fosrenol) was listed on the Pharmaceutical Benefits Scheme on 1 May 2009. The authority listing allows prescribing for the treatment of hyperphosphataemia in adults with chronic kidney disease who are on dialysis, but not in combination with sevelamer. |
| Teriparatide (Forteo) for severe osteoporosis NPS RADAR>Review>Health Professional Publication | Teriparatide is subsidised on the Pharmaceutical Benefits Scheme for severe established osteoporosis in people at very high risk of fracture who develop one or more new symptomatic fractures despite at least 12 months of continuous antiresorptive therapy. |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2009-05-01 00:00:00
The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of clinical circumstances of each patient.
RSS feed
